Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report details a specific share repurchase transaction executed on September 16, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 635,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,305 pence per share; lowest price paid was 1,294 pence per share.
- Treasury Shares Held: 505,396,816 shares (representing 9.07% of total issued share capital and 9.97% of total voting rights).
- Shares in Issue: 5,068,638,977 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 635,000 repurchased shares. Consequently, the Company's Treasury shareholding increased to 505,396,816 shares. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,068,638,977) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share percentage (9.07% of issued capital) for voting rights analysis.
- Review the remaining authority under the May 5, 2011 shareholder mandate for future repurchases.